Pegvaliase: Difference between revisions
Appearance
Content deleted Content added
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by Whywhenwhohow | #UCB_webform 177/257 |
update ib |
||
Line 26: | Line 26: | ||
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--> |
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--> |
||
| legal_BR_comment = |
| legal_BR_comment = |
||
| legal_CA = |
| legal_CA = Rx-only |
||
| legal_CA_comment = <ref>{{cite web | title=New Medicines Approved in 2018 | website=Health Canada | date=15 January 2020 | url=https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/meds-entry-watch-2018/new-medicines-approved-2018.html | access-date=28 May 2022}}</ref> |
|||
| legal_DE = <!-- Anlage I, II, III --> |
| legal_DE = <!-- Anlage I, II, III --> |
||
| legal_NZ = <!-- Class A, B, C --> |
| legal_NZ = <!-- Class A, B, C --> |
Revision as of 04:18, 29 May 2022
Clinical data | |
---|---|
Pronunciation | peg val' i ase |
Trade names | Palynziq |
Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618057 |
License data |
|
Pregnancy category | |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C15H30N2O5 |
Molar mass | 318.414 g·mol−1 |
3D model (JSmol) | |
| |
|
Pegvaliase, sold under the brand name Palynziq, is a medication for the treatment of the genetic disease phenylketonuria.[5][6] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[7]
It was approved by the Food and Drug Administration for use in the United States in 2018.[5] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[8]
References
- ^ a b "Palynziq". Therapeutic Goods Administration (TGA). 23 July 2021. Retrieved 5 September 2021.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "New Medicines Approved in 2018". Health Canada. 15 January 2020. Retrieved 28 May 2022.
- ^ a b "FDA approves a new treatment for PKU, a rare and serious genetic disease" (Press release). Food and Drug Administration. May 24, 2018.
- ^ Mahan KC, Gandhi MA, Anand S (April 2019). "Pegvaliase: a novel treatment option for adults with phenylketonuria". Current Medical Research and Opinion. 35 (4): 647–651. doi:10.1080/03007995.2018.1528215. PMID 30247930. S2CID 52813510.
- ^ "Palynziq". BioMarin Pharmaceutica.
- ^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
External links
- "Pegvaliase". Drug Information Portal. U.S. National Library of Medicine.